Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

Mark G. Kris, Richard J. Gralla, Rebecca A. Clark, Leslie B. Tyson

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

Three phase II studies of the serotonin antagonist GR38032F were conducted. In trial 1, 20 patients given initial chemotherapy with cisplatin at doses >=100 mg/m were randomized to receive three GR38032F doses (0.18 mg/kg) on an every-2-hour or every-4-hour schedule. In trial 2, eight similar patients were given three 0.04-mg/kg doses every 2 hours. In trial 3, 12 previously treated patients receiving cisplatin at 20-25 mg/m on 4 or 5 consecutive days each received three daily GR38032F doses (0.15 mg/kg) every 2 hours. In trial 1, 35% of the patients had no emesis (95%) confidence interval (CI), 16%-58%) and 55% had one or two emetic episodes (95% CI, 32%-76%). Results were similar between the every-2-hour and every-4-hour schedules. In trial 2, only one of eight patients (13%) had no vomiting (95% CI, 1%-50% ). In trial 3, in which previously treated patients were studied, complete control ranged from 75% on day 1 to 33% on day 3. Mild sedation, headache, and transient elevations of serum SGOT (AST) were observed. No extrapyramidal symptoms occurred. A dose of 0.15-0.18 mg/ kg every 2 hours for three iv doses is recommended. Further comparison and combination studies of GR38032F are warranted. [J Natl Cancer Inst 1989;81:42-46].

Original languageEnglish (US)
Pages (from-to)42-46
Number of pages5
JournalJournal of the National Cancer Institute
Volume81
Issue number1
DOIs
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin'. Together they form a unique fingerprint.

  • Cite this